Increased Prevalence of Myocardial Injury in Patients with SARS-CoV-2 Viremia.
Age Factors
COVID-19
/ blood
Cohort Studies
Female
Heart Diseases
/ blood
Hospitalization
/ statistics & numerical data
Humans
Male
Middle Aged
Myocardium
/ metabolism
Prevalence
SARS-CoV-2
/ isolation & purification
Troponin
/ blood
United States
/ epidemiology
Viral Load
/ methods
Viremia
/ diagnosis
COVID-19
Cardiac injury
Myocardial injury
SARS-CoV-2
Viral load
Journal
The American journal of medicine
ISSN: 1555-7162
Titre abrégé: Am J Med
Pays: United States
ID NLM: 0267200
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
15
09
2020
accepted:
16
09
2020
pubmed:
13
11
2020
medline:
4
5
2021
entrez:
12
11
2020
Statut:
ppublish
Résumé
Patients with coronavirus disease 2019 (COVID-19) have a high prevalence of detectable troponin and myocardial injury. In addition, a subset of patients with COVID-19 has detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral loads. The objective of this study was to understand the relationship among SARS-CoV-2 viremia, detectable troponin, and myocardial injury in hospitalized patients with COVID-19. SARS-CoV-2 plasma viral load was measured in plasma samples drawn from patients hospitalized for COVID-19 at 2 academic medical centers. Baseline characteristics and clinically obtained high-sensitivity cardiac troponin T (hs-cTnT) values were abstracted from the medical record. The main outcome was detectable hs-cTnT (≥6 ng/mL) and myocardial injury (hs-cTnT ≥14 ng/mL; >99th percentile for assay). A total of 70 hospitalized patients with COVID-19 were included in this study, with 39% females and median age 58 ± 17 years; 21 patients (30%) were found to have detectable SARS-CoV-2 viral load and were classified in the viremia group. Patients with viremia were significantly older than those without viremia. All of the patients with viremia (100%) had detectable troponin during hospitalization compared with 59% of patients without viremia (P = 0.0003). Myocardial injury was seen in 76% of patients with viremia and 38% of those patients without viremia (P = 0.004). Hospitalized patients with COVID-19 with SARS-CoV-2 viremia have a significantly higher prevalence of detectable troponin and myocardial injury during their hospitalization compared with patients who did not. This first report of the relationship among SARS-CoV-2 viremia, detectable troponin, and myocardial injury in patients with COVID-19 points to additional mechanistic pathways that require deeper study to understand the complex interplay among these unique findings, cardiovascular outcomes, and mortality in COVID-19.
Sections du résumé
BACKGROUND
Patients with coronavirus disease 2019 (COVID-19) have a high prevalence of detectable troponin and myocardial injury. In addition, a subset of patients with COVID-19 has detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral loads. The objective of this study was to understand the relationship among SARS-CoV-2 viremia, detectable troponin, and myocardial injury in hospitalized patients with COVID-19.
METHODS
SARS-CoV-2 plasma viral load was measured in plasma samples drawn from patients hospitalized for COVID-19 at 2 academic medical centers. Baseline characteristics and clinically obtained high-sensitivity cardiac troponin T (hs-cTnT) values were abstracted from the medical record. The main outcome was detectable hs-cTnT (≥6 ng/mL) and myocardial injury (hs-cTnT ≥14 ng/mL; >99th percentile for assay).
RESULTS
A total of 70 hospitalized patients with COVID-19 were included in this study, with 39% females and median age 58 ± 17 years; 21 patients (30%) were found to have detectable SARS-CoV-2 viral load and were classified in the viremia group. Patients with viremia were significantly older than those without viremia. All of the patients with viremia (100%) had detectable troponin during hospitalization compared with 59% of patients without viremia (P = 0.0003). Myocardial injury was seen in 76% of patients with viremia and 38% of those patients without viremia (P = 0.004).
CONCLUSIONS
Hospitalized patients with COVID-19 with SARS-CoV-2 viremia have a significantly higher prevalence of detectable troponin and myocardial injury during their hospitalization compared with patients who did not. This first report of the relationship among SARS-CoV-2 viremia, detectable troponin, and myocardial injury in patients with COVID-19 points to additional mechanistic pathways that require deeper study to understand the complex interplay among these unique findings, cardiovascular outcomes, and mortality in COVID-19.
Identifiants
pubmed: 33181107
pii: S0002-9343(20)30933-5
doi: 10.1016/j.amjmed.2020.09.046
pmc: PMC7654293
pii:
doi:
Substances chimiques
Troponin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
542-546Subventions
Organisme : NHLBI NIH HHS
ID : T32 HL094301
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
J Am Coll Cardiol. 2020 Aug 4;76(5):533-546
pubmed: 32517963
JAMA Cardiol. 2020 Nov 01;5(11):1265-1273
pubmed: 32730619
Prog Cardiovasc Dis. 2020 Sep - Oct;63(5):682-689
pubmed: 32512122
Clin Infect Dis. 2020 Nov 5;71(8):1937-1942
pubmed: 32301997
J Clin Microbiol. 2003 Oct;41(10):4531-6
pubmed: 14532178
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Am Heart J. 2020 Aug;226:29-44
pubmed: 32497913
JAMA Cardiol. 2020 Jul 1;5(7):831-840
pubmed: 32219363
JACC Basic Transl Sci. 2020 Apr 10;5(5):518-536
pubmed: 32292848
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Emerg Infect Dis. 2004 Sep;10(9):1550-7
pubmed: 15498155